AGM 2024 Presentation

November 22, 2024March 10, 2025 Alterity Therapeutics

2024

Post navigation

Target Market Determination – Placement Offer
Target Market Determination – Broker Offer
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM 2024 Presentation

Related Posts

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Prana Announces RD Refund

ABC Radio Jon Faine Program features Prana IMAGINE trial for Alzheimer’s disease